Fresenius Medical Care AG & Co. KGaA (ETR:FME – Get Rating) has been assigned a €82.20 ($87.45) price objective by stock analysts at Berenberg Bank in a research report issued to clients and investors on Tuesday, Borsen Zeitung reports. Berenberg Bank’s price objective indicates a potential upside of 46.58% from the stock’s previous close.
FME has been the subject of several other reports. Barclays set a €68.00 ($72.34) price target on Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, April 26th. Jefferies Financial Group set a €53.00 ($56.38) price target on Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, February 22nd. Warburg Research set a €62.00 ($65.96) price objective on Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, May 10th. Deutsche Bank Aktiengesellschaft set a €58.00 ($61.70) price target on Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, March 22nd. Finally, UBS Group set a €75.00 ($79.79) price objective on Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, May 11th.
FME stock traded down €0.22 ($0.23) during trading on Tuesday, hitting €56.08 ($59.66). The company had a trading volume of 385,545 shares, compared to its average volume of 704,197. The company has a quick ratio of 0.76, a current ratio of 1.10 and a debt-to-equity ratio of 95.29. The firm has a 50-day moving average price of €59.98 and a 200-day moving average price of €58.26. Fresenius Medical Care AG & Co. KGaA has a 1-year low of €50.98 ($54.23) and a 1-year high of €71.14 ($75.68). The firm has a market cap of $16.43 billion and a PE ratio of 16.95.
Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
- Veeva Systems: Increasing NDR and Other Wins
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Institutions Buy The Dip In Petco Health and Wellness Company
- Autozone Edges Past Advanced Auto Parts In Q1 2022
- CrowdStrike: A Cybersecurity Unicorn
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.